SCHEMBL19970873

SCHEMBL19970873

Cc1ccc(NC(=O)N2CCN(Cc3ccc4nc(-c5ccccc5)[nH]c4c3)CC2)cc1

nearest known ligand 0.61

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
FAAH O00519 12/20 0.61
DGAT1 O75907 2/20 0.55
HTT P42858 1/20 0.54
MMP2 P08253 2/20 0.54
MMP9 P14780 2/20 0.54
MMP8 P22894 2/20 0.54
MMP13 P45452 2/20 0.54
TP53 P04637 1/20 0.52
AURKA O14965 1/20 0.51
CDK1 P06493 1/20 0.51
CCNB1 P14635 1/20 0.51
CDK2 P24941 1/20 0.51
AURKB Q96GD4 1/20 0.51
HPSE Q9Y251 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19970872 0.93 FAAH (0.61) FAAHDGAT1HTT
SCHEMBL19970868 0.91 ALDH1A1 (0.55) FAAHDGAT1HTTTP53AURKA
SCHEMBL19970728 0.89 FAAH (0.63) FAAHAURKACDK1CCNB1CDK2
SCHEMBL19970782 0.88 FAAH (0.57) FAAHHTTTP53
SCHEMBL19970871 0.85 FAAH (0.58) FAAHHTTTP53
SCHEMBL19970867 0.84 FAAH (0.54) FAAHDGAT1HTT
SCHEMBL19970727 0.81 FAAH (0.63) FAAH
SCHEMBL19970781 0.81 FAAH (0.57) FAAHHTTTP53
SCHEMBL32660773 0.81 FAAH (0.57) FAAHHTTTP53
SCHEMBL19970830 0.80 FAAH (0.56) FAAHDGAT1TP53AURKACDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-25 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION UNIVERSITE D'ORLEANS (FR) 2021-09-23 US disclosed
WO-2018050771-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-22 WO disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed
EP-3296297-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2018-03-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292350-A1 BENZIMIDAZOL DERIVATIVES FOR TREATING FILOVIRUS INFECTION FIP1L1, ZC3HAV1, MAVS FAAH 3154/4885DGAT1 4320/4885HTT 4001/4885
US-11479571-B2 Benzimidazol derivatives for treating filovirus infection FIP1L1, ZC3HAV1, MAVS FAAH 3154/4885DGAT1 4320/4885HTT 4001/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.